Citius Oncology: LYMPHIR Wholesaler Units Jump 120% in Fiscal Q4
CTOR sits 20% above its 52-week low of $0.491 on elevated volume (7.7× avg).
Summary
Citius Oncology reported preliminary fiscal Q4 2026 LYMPHIR unit sales to U.S. wholesalers of 792, up 120% from 360 in fiscal Q3, with 54 institutions now having ordered the drug versus 44 as of August 14. The figures are unaudited and full fiscal 2026 results are expected in December 2026.
Key Events · Earnings and Guidance · CTOR
-
Wholesaler Units Up 120% Sequentially
U.S. wholesalers purchased 792 LYMPHIR units in fiscal Q4 2026 versus 360 in fiscal Q3 2026, a 120% increase, per preliminary unaudited figures.
-
Institutional Ordering Base Widens
54 institutions have now ordered LYMPHIR, up from 44 as of August 14, 2026; management says it is more than halfway to its goal of formulary placement at 100 priority institutions by calendar year-end.
-
Vial Orders Nearly Flat
Prescribing centers ordered 950 vials from wholesalers in fiscal Q4 versus 926 in fiscal Q3, so the unit-sales jump outpaces end-demand and may partly reflect wholesaler stocking.
-
Preliminary, Unaudited; 10-K in December
Figures are management estimates not reviewed by the auditor; complete fiscal Q4 and fiscal year 2026 results are expected in December 2026 with the Annual Report on Form 10-K.
Analysis · CTOR · Life Sciences
Wholesaler unit purchases more than doubled sequentially, to 792 from 360, and the number of institutions that have ordered LYMPHIR rose to 54 from 44 as of the August 14 update. That is the first hard evidence the expanded commercial team's nationwide coverage is converting into demand—a critical signal given the company's going-concern warning and Nasdaq delisting risk. The caveat: vial orders by prescribing centers barely moved (950 vs 926), so the unit jump partly reflects wholesaler stocking rather than end-demand. The figures are preliminary and unaudited, with full fiscal 2026 results due in December 2026 with the 10-K.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTOR was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.4M. The 52-week trading range was $0.49 to $1.93. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.